Source
Author: unknown
Eli Lilly to buy genetic medicine developer Akouos for $487 million [Deals Market Headlines | Breaking Stock Market News | Reuters]
Related Posts
Bayer Bolsters Ophthalmology Portfolio with $2.45 Billion Acquisition of Perfuse Therapeutics
TL;DR Bayer AG announced on May 6, 2026, its acquisition of Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment and $2.15 billion in milestones. The deal secures...
UCB Acquires Candid Therapeutics for $2.2 Billion in High-Stakes Bet on ‘Immune Reset’
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on...
Sun Pharma Nears $12 Billion Acquisition of Organon: A New Frontier for Indian Pharma
TL;DR Mumbai-based Sun Pharmaceutical Industries Ltd. is finalizing a binding $12 billion offer for Organon & Co., marking the largest overseas acquisition in Indian pharma history. The deal is...
Merck’s $6.7 Billion Bid for Terns Pharma: A Strategic Play for Metabolic Leadership
TL;DR Merck & Co. has launched a $6.7 billion all-cash unsolicited offer for Terns Pharma, a biotech firm specializing in small-molecule drug candidates for metabolic disorders like NASH. The...